ALK-positive NSCLC – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
ALK-positive NSCLC Market Outlook
Thelansis’s “ALK-positive NSCLC Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential ALK-positive NSCLC treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
ALK-positive NSCLC Overview
In a
subset of non-small cell lung cancer (NSCLC) patients, a rare occurrence of
rearrangements exists within the Anaplastic lymphoma kinase (ALK) gene. These
alterations induce perpetual activation of the ALK kinase, subsequently leading
to the formation of ALK-driven tumors. Individuals harboring such
rearrangements exhibit heightened sensitivity to ALK inhibitors like
crizotinib, ceritinib, and alectinib. ALK-positive NSCLC occurs in
approximately 1 out of every 25 NSCLC cases. ALK-positive tumor patients
typically skew towards a younger demographic and are more commonly found among
never-smokers or light smokers. Indeed, ALK rearrangements are observed in 12%
of never-smokers, contrasting to the mere 2% incidence in former or current
smokers. Notably, ALK rearrangements seldom coincide with activating mutations
in EGFR or KRAS. In comparison to those with EGFR-mutant NSCLC, patients with
ALK-positive tumors exhibit a higher likelihood of being male.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment